IRONWOOD PHARMACEUTICALS, INC.: 10-Q filed 2016-05-10
What IRONWOOD PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-05-10 (fiscal Q1 2016): 28 published measures, 56 facts as tagged in accession 0001104659-16-119768.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2016-05-10
- Fiscal period
- fiscal Q1 2016
- Accession
- 0001104659-16-119768 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All IRONWOOD PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 603,325,000 | USD | |
| At 2015-12-31 | 619,121,000 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 90,935,000 | USD | |
| At 2015-12-31 | 95,125,000 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 280,926,000 | USD | |
| At 2015-12-31 | 261,287,000 | USD | |
| At 2015-03-31 | 63,692,000 | USD | |
| At 2014-12-31 | 74,297,000 | USD |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 1,008,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 1,987,000 | USD | 90 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 66,042,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 28,932,000 | USD | 90 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | -1,123,412,000 | USD | |
| At 2015-12-31 | -1,110,115,000 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 19,446,000 | USD | |
| At 2015-12-31 | 21,075,000 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 6,806,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 5,426,000 | USD | 90 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -1,968,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -28,067,000 | USD | 90 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 495,701,000 | USD | |
| At 2015-12-31 | 500,205,000 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 9,907,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 5,220,000 | USD | 90 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 78,113,000 | USD | |
| At 2015-12-31 | 76,465,000 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 4,741,000 | USD | |
| At 2015-12-31 | 8,589,000 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 908,000 | USD | |
| At 2015-12-31 | 2,884,000 | USD |
Cost of revenue
Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | 12,000 | USD | 90 |
Selling, general and administrative expense
Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 36,168,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 30,346,000 | USD | 90 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 31,842,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 26,641,000 | USD | 90 |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 29,000 | USD | |
| At 2015-12-31 | -86,000 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 78,421,000 | USD | |
| At 2015-12-31 | 77,681,000 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 58,975,000 | USD | |
| At 2015-12-31 | 56,606,000 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 2,243,000 | USD | |
| At 2015-12-31 | 2,628,000 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 10,120,000 | USD | |
| At 2015-12-31 | 10,120,000 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 7,731,000 | USD | |
| At 2015-12-31 | 6,293,000 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -13,182,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -33,200,000 | USD | 90 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -13,297,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -33,222,000 | USD | 90 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | 2,833,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | 2,891,000 | USD | 90 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-01-01 to 2016-03-31 | -11,329,000 | USD | 91 |
| 2015-01-01 to 2015-03-31 | -5,155,000 | USD | 90 |
Change in inventories
The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-01-01 to 2015-03-31 | -4,000 | USD | 90 |
Inspect the source
- Entity
- IRONWOOD PHARMACEUTICALS, INC. / CIK 0001446847
- Captured
- 2026-09-20T09:04:45.983Z
- SEC response SHA-256
e907547bc46d38e028ac317d678e19520bc4135085f9133b1b1f54dc9a6016a4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001446847.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))